Inter‐ and Intrarater Reliability of the Hurley Staging for Hidradenitis Suppurativa – Ovadja – – British Journal of Dermatology

Background

Hidradenitis suppurativa (HS) is a chronic, inflammatory and recurrent skin disease. Different staging instruments have been suggested, but none has achieved universal acceptance. Despite the fact that the Hurley staging is one of the most widely applied HS disease severity staging instruments, it has not been validated.

Objective

To determine the inter‐ and intrarater reliability of the Hurley staging.

Methods

Fifteen raters (5 plastic surgeons, 5 general surgeons and 5 dermatologists) independently staged 30 photos of HS patients according to the Hurley staging at T1 and T2. Reliability was assessed using kappa statistics and multivariable logistic regressions were used to determine independent risk factors for photos with discordant staging.

Results

Interrater reliability was moderate for the three stages of HS (κ = 0·59; 95% CI, 0·48‐0·70). It was moderate for Hurley stage I (κ = 0·45; 95% CI, 0·32‐0·55) and stage II (κ = 0·51; 95% CI, 0·31‐0·71), and it was almost perfect for stage III (κ = 0·81; 95% CI, 0·62‐1·00). The intrarater reliability was substantial for all stages and all raters (κ = 0·65; 95% CI, 0·58‐0·72). For stage I it was moderate (κ = 0·50; 95% CI, 0·38‐0·62), for stage II it was substantial (κ = 0·62; 95% CI, 0·51‐0·73) and for stage III it was almost perfect (κ = 0·82; 95% CI, 0·77‐0·87). Hurley stage II and III were less likely to result in discordant staging compared to Hurley stage I (OR 0·47, 95% CI 0·29‐0·77 and OR 0·21, 95% CI 0·12‐0·38 respectively). The mean time spent on staging a photo was 14 seconds.

Conclusions

The Hurley staging is reliable for rapid severity assessment of HS, with a moderate interrater and substantial intrarater reliability for all stages. It is best for assessing Hurley stage III, which is an indication for surgery.

This article is protected by copyright. All rights reserved.

Source link

Petroleo Br.Adr (Put) (PBR) Share Price Rose While Exane Derivatives Increased Holding by $672.00 Million; Carmignac Gestion Raised Chemocentryx (CCXI) Stake by $3.30 Million – The Financial Examiner

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

Carmignac Gestion increased its stake in Chemocentryx Inc (CCXI) by 26.83% based on its latest 2018Q3 regulatory filing with the SEC. Carmignac Gestion bought 275,273 shares as the company’s stock declined 9.75% with the market. The institutional investor held 1.30M shares of the health care company at the end of 2018Q3, valued at $16.45M, up from 1.03M at the end of the previous reported quarter. Carmignac Gestion who had been investing in Chemocentryx Inc for a number of months, seems to be bullish on the $552.75M market cap company. The stock increased 4.29% or $0.45 during the last trading session, reaching $10.94. About 295,935 shares traded or 47.43% up from the average. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 69.59% since December 30, 2017 and is uptrending. It has outperformed by 69.59% the S&P500. Some Historical CCXI News: 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 09/03/2018 ChemoCentryx 4Q EPS 80c

Exane Derivatives increased its stake in Petroleo Br.Adr (Put) (PBR) by 240% based on its latest 2018Q3 regulatory filing with the SEC. Exane Derivatives bought 12,000 shares as the company’s stock rose 24.82% while stock markets declined. The institutional investor held 17,000 shares of the oil & gas production company at the end of 2018Q3, valued at $952.00 million, up from 5,000 at the end of the previous reported quarter. Exane Derivatives who had been investing in Petroleo Br.Adr (Put) for a number of months, seems to be bullish on the $82.84B market cap company. The stock increased 2.00% or $0.26 during the last trading session, reaching $13.03. About 16.52M shares traded. Petróleo Brasileiro S.A. – Petrobras (NYSE:PBR) has risen 41.31% since December 30, 2017 and is uptrending. It has outperformed by 41.31% the S&P500. Some Historical PBR News: 29/05/2018 – BRAZIL’S TEMER SAYS PETROBRAS REFORMS WILL NOT BE UNDONE BY FUEL PRICE CONCESSIONS; 13/04/2018 – PETROBRAS SAYS FINANCING MATURES IN 2029, RESOURCES TO BE USED TO ACQUIRE GOODS AND SERVICES FROM UK SUPPLIERS – STATEMENT; 15/03/2018 – PETROBRAS SEES NET DEBT AT $77B AT END 2018; 23/05/2018 – Brazil truck strike forces Petrobras to slash diesel prices; 08/05/2018 – Petrobras Is Acting Like an Oil Major, It’s Working (Correct); 19/04/2018 – Macquarie, Mubadala, Engie bid for Brazil gas pipeline network owned by Petrobras; 25/04/2018 – CNBC Wires: Petrobras scraps Liquigas IPO, eyes antitrust risk in sale; 14/03/2018 – PETROBRAS SAYS IT’S ASSESSING ALTERNATIVES TO SELL LIQUIGAS; 28/03/2018 – BRAZIL’S STATE-RUN OIL COMPANY PETROBRAS SAYS COMPLETED HEDGE TO PROTECT PRICE FOR 128 MILLION BARRELS OF OIL PRODUCTION IN 2018; 13/03/2018 – BW OFFSHORE LTD BWO.OL – BW OFFSHORE HAS RECEIVED NOTICE FROM PETROBRAS OF EXERCISE OF A ONE-YEAR EXTENSION OF CONTRACTS RELATING TO FPSO CIDADE DE SÃO MATEUS

Investors sentiment decreased to 0.98 in Q3 2018. Its down 0.61, from 1.59 in 2018Q2. It turned negative, as 14 investors sold CCXI shares while 29 reduced holdings. 13 funds opened positions while 29 raised stakes. 26.80 million shares or 1.64% more from 26.37 million shares in 2018Q2 were reported. Landscape Cap Management Ltd Co holds 0.01% or 10,285 shares. Renaissance Ltd Liability Corporation holds 0.01% or 772,281 shares in its portfolio. Dimensional Fund Advisors Lp holds 0% or 547,771 shares in its portfolio. American Int Grp Inc has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 14,904 shares. Tower Llc (Trc) owns 626 shares for 0% of their portfolio. Strs Ohio holds 0% in ChemoCentryx, Inc. (NASDAQ:CCXI) or 52,400 shares. California Public Employees Retirement Systems holds 67,452 shares or 0% of its portfolio. D E Shaw And stated it has 259,837 shares. Pnc Finance Services Grp Inc accumulated 74 shares. Moreover, Northern has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 300,109 shares. Moreover, Meeder Asset Mngmt has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). State Street holds 0% or 494,984 shares in its portfolio. Barclays Public Limited Liability Co has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). 17,811 are held by Sectoral Asset Management. Dorsey Wright reported 975 shares.

Carmignac Gestion, which manages about $11.80 billion US Long portfolio, decreased its stake in Stryker Corp (NYSE:SYK) by 638,480 shares to 959,076 shares, valued at $170.41M in 2018Q3, according to the filing. It also reduced its holding in Graftech International Ltd by 35,976 shares in the quarter, leaving it with 964,024 shares, and cut its stake in Nutrien Ltd.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Globenewswire.com which released: “ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress – GlobeNewswire” on May 23, 2018, also Globenewswire.com with their article: “ChemoCentryx to Present at Two Upcoming Investor Conferences – GlobeNewswire” published on May 30, 2018, Globenewswire.com published: “New Research Coverage Highlights Ralph Lauren, CECO Environmental, PRA Group, ChemoCentryx, SunCoke Energy Partners, and Delek US — Consolidated Revenues, Company Growth, and Expectations for 2018 – GlobeNewswire” on November 27, 2018. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Seekingalpha.com and their article: “ChemoCentryx, Inc. (CCXI) CEO Dr. Thomas Schall on Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” published on August 09, 2018 as well as Seekingalpha.com‘s news article titled: “ChemoCentryx terminates previously announced common stock offering – Seeking Alpha” with publication date: September 28, 2018.

Since October 16, 2018, it had 0 insider purchases, and 3 insider sales for $86.26 million activity. Another trade for 7,211 shares valued at $86,554 was made by Schall Thomas J. on Wednesday, November 7. GLAXOSMITHKLINE PLC sold $85.85 million worth of stock or 7.34M shares.

Among 8 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 1 Sell and 3 Hold. Therefore 50% are positive. ChemoCentryx had 12 analyst reports since September 3, 2015 according to SRatingsIntel. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) earned “Sell” rating by Zacks on Monday, September 21. The rating was maintained by Canaccord Genuity with “Buy” on Monday, November 12. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) has “Sell” rating given on Thursday, September 3 by Zacks. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) earned “Mkt Outperform” rating by JMP Securities on Tuesday, February 21. The company was downgraded on Tuesday, August 14 by JP Morgan. The company was maintained on Tuesday, March 13 by JP Morgan. The firm has “Buy” rating given on Thursday, August 10 by JMP Securities. The rating was maintained by Cowen & Co with “Hold” on Tuesday, August 8.

More notable recent Petróleo Brasileiro S.A. – Petrobras (NYSE:PBR) news were published by: Benzinga.com which released: “Wall Street Warming Up To Petrobras (NYSE:PBR) – Benzinga” on October 08, 2018, also Seekingalpha.com with their article: “Petrobras Sinks 45% In A Month… Time To Buy? – Seeking Alpha” published on June 25, 2018, Seekingalpha.com published: “New CEO seen curbing political interference, analysts say – Seeking Alpha” on November 19, 2018. More interesting news about Petróleo Brasileiro S.A. – Petrobras (NYSE:PBR) were released by: Seekingalpha.com and their article: “Brazil’s Most Valuable Company: Petrobras Is Back – Seeking Alpha” published on October 10, 2018 as well as Investorplace.com‘s news article titled: “15 Stocks Facing Big Political Risk in 2019 – Investorplace.com” with publication date: December 18, 2018.

Among 16 analysts covering Petroleo Brasileiro Petrobras SA (NYSE:PBR), 3 have Buy rating, 4 Sell and 9 Hold. Therefore 19% are positive. Petroleo Brasileiro Petrobras SA had 49 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was initiated by Credit Suisse with “Underperform” on Tuesday, January 12. Credit Suisse maintained Petróleo Brasileiro S.A. – Petrobras (NYSE:PBR) rating on Friday, May 26. Credit Suisse has “Buy” rating and $12.4000 target. The stock of Petróleo Brasileiro S.A. – Petrobras (NYSE:PBR) earned “Hold” rating by UBS on Friday, June 8. Credit Suisse maintained it with “” rating and $11 target in Thursday, March 23 report. On Thursday, May 24 the stock rating was downgraded by Bank of America to “Hold”. JP Morgan upgraded the shares of PBR in report on Tuesday, May 24 to “Neutral” rating. The stock of Petróleo Brasileiro S.A. – Petrobras (NYSE:PBR) earned “Neutral” rating by Credit Suisse on Friday, August 26. The rating was upgraded by Bank of America to “Buy” on Thursday, May 10. The stock of Petróleo Brasileiro S.A. – Petrobras (NYSE:PBR) earned “Underperform” rating by JP Morgan on Thursday, February 4. The rating was upgraded by Morgan Stanley to “Equal-Weight” on Tuesday, March 22.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

Tekla Capital Management Lifted By $1.81 Million Its Edwards Lifesciences (EW) Position; Shorts at Xbiotech (XBIT) Lowered By 5.26% – The DMinute

Edwards Lifesciences Corporation (NYSE:EW) Logo

Xbiotech Inc (NASDAQ:XBIT) had a decrease of 5.26% in short interest. XBIT’s SI was 1.65 million shares in December as released by FINRA. Its down 5.26% from 1.74 million shares previously. With 23,200 avg volume, 71 days are for Xbiotech Inc (NASDAQ:XBIT)’s short sellers to cover XBIT’s short positions. The SI to Xbiotech Inc’s float is 8.38%. The stock increased 0.60% or $0.03 during the last trading session, reaching $4.99. About 90,018 shares traded or 6.32% up from the average. XBiotech Inc. (NASDAQ:XBIT) has declined 7.38% since December 29, 2017 and is downtrending. It has underperformed by 7.38% the S&P500. Some Historical XBIT News: 16/04/2018 – XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 02/04/2018 – XBIOTECH INC – HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG; 16/04/2018 – XBIOTECH INC – CONDUCTING FINAL PREPARATIONS FOR STUDY LAUNCH INCLUDING FIRST CLINICAL SITE INITIATION SCHEDULED LATER THIS MONTH; 02/04/2018 – XBIOTECH – WILL USE ITS TECHNOLOGY TO ADVANCE DEVELOPMENT OF TRUE HUMAN(TM )ANTI-NY-ESO-1 MONOCLONAL ANTIBODY, 12D7; 02/04/2018 – XBIOTECH IN-LICENSES ANTI-NY-ESO-1 ANTIBODY FROM CT ATLANTIC; 02/04/2018 XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer; 20/04/2018 – DJ XBiotech Inc, Inst Holders, 1Q 2018 (XBIT); 16/04/2018 – XBIOTECH INC – UPCOMING PHASE 2 CLINICAL STUDIES IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) AND HIDRADENITIS SUPPURATIVA (HS); 16/04/2018 – XBIOTECH INC – CO WOULD EVALUATE A NEW SUBCUTANEOUS FORMULATION OF CO’S TRUE HUMAN MONOCLONAL ANTIBODY, MABP1, IN TWO SEPARATE PHASE 2 STUDIES; 22/05/2018 – XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis

Tekla Capital Management Llc increased Edwards Lifesciences Corporation (EW) stake by 15.72% reported in 2018Q3 SEC filing. Tekla Capital Management Llc acquired 10,421 shares as Edwards Lifesciences Corporation (EW)’s stock rose 13.75%. The Tekla Capital Management Llc holds 76,696 shares with $13.35 million value, up from 66,275 last quarter. Edwards Lifesciences Corporation now has $31.44B valuation. The stock increased 0.27% or $0.4 during the last trading session, reaching $150.41. About 846,311 shares traded. Edwards Lifesciences Corporation (NYSE:EW) has risen 37.86% since December 29, 2017 and is uptrending. It has outperformed by 37.86% the S&P500. Some Historical EW News: 24/04/2018 – Edwards Lifesciences 1Q Net $206.6M; 24/04/2018 – EDWARDS LIFESCIENCES – CONTINUES TO EXPECT THVT FY UNDERLYING SALES GROWTH RATE TO BE AT HIGHER END OF 11 PCT TO 15 PCT; 21/03/2018 – EDWARDS LIFESCIENCES – NOW EXPECTS THAT EUROPEAN LAUNCH OF SAPIEN 3 ULTRA SYSTEM WILL OCCUR LATER IN 2018; 01/05/2018 – EDWARDS LIFESCIENCES IN ACCELERATED SHARE BUYBACK PACT; 24/04/2018 – EDWARDS LIFESCIENCES 1Q ADJ. EPS $1.22, EST. $1.11; 20/04/2018 – DJ Edwards Lifesciences Corporation, Inst Holders, 1Q 2018 (EW); 24/04/2018 – Edwards Lifesciences Sees 2Q Adj EPS $1.05-Adj EPS $1.15; 24/04/2018 – Edwards Lifesciences 1Q EPS 96c; 21/03/2018 – Edwards Completes Enrollment In PARTNER 3 Low-Risk CT Sub-Study, Updates Timeline For SAPIEN 3 Ultra System Launch In Europe; 24/04/2018 – Edwards Lifesciences Raises 2018 View To Adj EPS $4.50-Adj EPS $4.70

More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Nasdaq.com which released: “Mid-Afternoon Market Update: Dow Up Over 600 Points; Immunomedics Shares Surge – Nasdaq” on December 26, 2018, also Globenewswire.com with their article: “XBiotech Announces Successful Completion of GMP Audit – GlobeNewswire” published on December 03, 2018, Nasdaq.com published: “Health Care Sector Update for 12/12/2018: XBIT, SGYP, NBIX, MRNS, JNJ, PFE, MRK, ABT, AMGN – Nasdaq” on December 12, 2018. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: Nasdaq.com and their article: “XBiotech Announces Publication of Post-Hoc Analysis for Phase III Colorectal Cancer Study – Nasdaq” published on December 13, 2018 as well as Nasdaq.com‘s news article titled: “XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease – Nasdaq” with publication date: December 12, 2018.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $178.74 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.

Tekla Capital Management Llc decreased Mckesson Corporation (NYSE:MCK) stake by 15,850 shares to 82,947 valued at $11.00 million in 2018Q3. It also reduced Centene Corporation (NYSE:CNC) stake by 17,950 shares and now owns 166,869 shares. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was reduced too.

Edwards Lifesciences Corporation (NYSE:EW) Ratings Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

Analysed by Business Growth, Development Factors, Applications, and Future Prospects – The Comic Journal

Computers

Global Computers Market report provides comprehensive analysis of regional market. The report delivers information on major players like manufacturers, suppliers, distributors, traders, customers, investors etc., major types, major applications etc. Data type include capacity, production, market share, price, revenue, cost, gross, gross margin, growth rate, consumption, import, export etc. 

Overview of the Computers Market

Hidradenitis suppurativa is a rare, inflammatory skin condition that begins as small and painful pimples on the skin. This medical condition is most common between the ages of 20-40 years. Prevalence of hidradenitis suppurativa is three times more common in females than in males., ,

Computers Market competition by top manufacturers/ Key player/ Economy by Business Leaders:

  • xoSmithKline, Johnson & Johnson, Merck, Pfizer, AbbVie, Allergan, AstraZeneca, ,.   And More……

Get Access to Report Sample: http://www.360marketupdates.com/enquiry/request-sample/13121205

Scope of the Report:

This report focuses on the Computers in Global market, especially in North America, Europe, Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Computers Market Segment by Regions, regional analysis covers

  • North America (USA, Canada and Mexico)
  • Europe (Germany, France, UK, Russia and Italy)
  • Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
  • South America (Brazil, Argentina, Columbia etc.)
  • Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Computers Market Segment by Type, covers:

  • Medications
  • Surgery
  • Others

    Computers Market Segment by Applications, can be divided into:

  • Medications
  • Surgery
  • Others

    Target Audience of Computers Market:

    • Manufacturer / Potential Investors
    • Traders, Distributors, Wholesalers, Retailers, Importers and Exporters.
    • Association and government bodies.

    Ask our Industry Experts: https://www.360marketupdates.com/enquiry/pre-order-enquiry/13121205

    Key questions answered in the report:

    • What will the market growth rate of Computers market in 2023?
    • What are the key factors driving the global Computers market?
    • Who are the key manufacturers in Computers market space?
    • What are the market opportunities, market risk and market overview of the Computers market?
    • What are sales, revenue, and price analysis of top manufacturers of Computers market?
    • Who are the distributors, traders and dealers of Computers market?
    • What are the Computers market opportunities and threats faced by the vendors in the global Computers industries?
    • What are sales, revenue, and price analysis by types and applications of Computers market?
    • What are sales, revenue, and price analysis by regions of Computers industries?
  • Source link

    Hidradenitis Suppurativa in Layman's Terms | My HS Story Part One

    Thank you so much for tuning in! Please like, comment, and SUBSCRIBE to join me as I journey to remission from HS.

    Source link

    Hidradenitis Suppurativa: Top Ten Tips

    Get it in : http://bit.ly/2EXEwRk Hidradenitis Suppurativa: Top Ten Tips Here are some top tips for the management and treatment of Hidradenitis …

    Source link

    The trials and tribulations of medical marijuana

    From a young age, Eilat resident Tomer Marciano, 29, suffered from large and painful ulcerated skin blisters. When Tomer was 23, he discovered the name of his condition: Hidradenitis suppurativa, a rare, chronic skin condition that features small, painful lumps under the skin.

     



     

    After his diagnosis, Tomer began taking antibiotics with the hope that they would heal the inflammation.

     

    “I received very high doses of antibiotics for two years. It was a very difficult period for my body,” he said. After a year and a half of treatment I could not leave my house. I had nine areas of the body that were bleeding intermittently. Due to the pain, it took 40 minutes to get out of bed. My mother would make sure that I did not bleed to death during my showers. I could not work and my social life ground to a halt. I had to learn how to live again.”

     

    Tomer Marciano: It took 40 minutes to get out of bed

    Tomer Marciano: It took 40 minutes to get out of bed

     

    Marciano set out to locate others with his rare condition via internet forums and made contact with two people suffering from the same ailment. They told him that thanks to the use of cannabis, the disease was in regression.

     

    Marciano began to use cannabis as well and quickly discovered that it helped alleviate his pain and with an intake of 30-40 grams a month he has experienced a significant decrease in the number of outbreaks.

     

    He set out on a journey to discover anything that can alleviate his condition. He set out for the US state of Colorado, where cannabis was legalized in 2014.

     

    “Because of legalization, I had access to a wide variety of quality substances which enabled me to get a good picture of the effects of each strain,” he said. “I went through dozens of dispensaries before I found the  variety that was right for me.”

     

    Marciano discovered that a combination of smoking certain varieties of medical cannabis, together with the application of “Rick Simpson” oil (named for its discoverer) worked wonders for him.

     

    “The oil has a very harsh effect on the body, but its healing properties are amazing… Within three and a half months of landing in Colorado, I was 95% cured and was able to fully function. By then I had decreased my intake of grass and decided to return to Israel in order to receive the treatment I need near my family and friends,” he said.

     

    But when he returned to Israel, Tomer encountered serious difficulties. “My application for medical cannabis was rejected. The Health Ministry insisted that I find conventional methods of dealing with my disease and provide an explanation why I need cannabis for a disease not yet sufficiently researched,” he said.

     

    “Since returning to Israel my situation has deteriorated. In Colorado I was almost entirely healed; I was at stage one, almost stage zero, of the disease, but in Israel I was again categorized as stage two.,”  

     

    Only after four years of struggle did he find a doctor willing to recommend prescribing him with 100 grams of cannabis a month, but the state only allowed him half that.

     

    “What I had been taking per week in the US is what they allow me per month in Israel,” he said. “I am forced to purchase cannabis illegally because I am not willing to become disabled again. Currently I am taking 130 grams a month, only 50 of it from the government. But those additional 80 grams make all the difference between sitting at home unproductive and being able to lead a normal life. At my last appointment, the doctor told me that I look the best he’s ever seen me. I cannot allow myself to endure what I have been through again.”

     

    Over the last two years, Tomer has volunteered at a medical cannabis organization and begun studying plant sciences at the Hebrew University’s School of Agriculture. “This is my way to affect change from within. This plant changed my life and now I want to help others change their lives.”

     

    In the seven years since the government legalized medical cannabis, it has become clear that it is not a passing fad. More than 42,000 Israeli patients hold a Health Ministry medical cannabis license for a variety of conditions including cancer, chronic pain, degenerative diseases and psychiatric conditions.

     

    For most of these patients it is the difference between a manageable or normal life versus one of unbearable suffering. And demand is only rising as more and more research studies show the affectivity of medical cannabis with more and more diseases.

     

    On the other hand, it is also clear that cannabis is not a magic pill and that it can have side effects.

     

    But tens of thousands of patients who can benefit from cannabis to alleviate their pain need to fight the bureaucracy and established medical norms to obtain a license. They are often left with one option: turning to the black market or living a life of pain and suffering.

     

    These are not drug addicts or recreational tokers seeking subsidies, but rather people who find themselves at the extreme end of the medical spectrum. Nevertheless, the state creates numerous hurdles for them.

     

    In order to understand why, in a country which prides itself for being highly developed, tens of thousands of patients experience difficulty in obtaining the plant that can change their lives, we must understand the procedure necessary for obtaining medical cannabis.

     

    The first stop in the process is obtaining a doctor’s recommendation and sending it to the medical cannabis unit at the Health Ministry. The doctor must be a specialist in the disease the patient is suffering from. Family physicians cannot issue a referral. Thus the ministry eliminated the option of getting a referral from the doctor who knows the patient the best.

     

    After all the necessary documents are received, a senior doctor reviews the application and decides whether to issue a license.

     

    But the ministry’s guidelines specify that cannabis only be a last resort, after all other medical options are exhausted. This means that even patients who clearly ought to be eligible to receive medical cannabis must first undergo other treatments, often with harsh side effects, for a specified amount of time before becoming eligible for a cannabis license. In other words: let’s first eliminate all the conventional medical options before resorting to cannabis.

     

    Medical cannabis  (Photo: Shutterstock)

    Medical cannabis (Photo: Shutterstock)

     

    The abovementioned directive can often be absurd. Patients suffering from Crohn’s disease, a severe gastrointestinal inflammatory disease, only become eligible for medical cannabis after eliminating the option of removing part of their intestines, a treatment involving considerable risk.

      

    Patients suffering from chronic pain must first undergo a year of treatment at a pain clinic and “conventional” treatments involving severe side effects including the danger of drug addiction.

     

    Moreover, oncology patients are only eligible for medical cannabis while undergoing chemotherapy and up to six months afterwards, despite the fact that many side effects caused by the cancer or the treatments can last for much longer.

     

    Some patients have resorted to unusual solutions such as purchasing the required conventional medications for as long as required, often at considerable cost, but not using them, only in order to become eligible for medical cannabis.

     

    Even after the application form is filled out and signed by a medical specialist, the medical cannabis unit only begins to process the request after all of the necessary forms are submitted.

     

    Herein lies another difficulty: the department is so overloaded with requests that it is almost impossible to get a representative on the phone. Even one who does manage to avoid the busy signal will have to wait an excruciatingly long time before getting someone on the line. Even then their problem is not necessarily addressed. Representatives of the medical cannabis division often fail to provide answers to applicant’s questions and can only give limited information regarding the status of a submitted application.

     

    “As of today, we are assisting more than one hundred patients who don’t know the status of their application,” says Dana Bar-On, chair of the Medical Cannabis Association. “The system cannot deal with the tens of thousands of patients whom it is supposed to help.”

     

    Dana Bar-On: The system is overloaded

    Dana Bar-On: The system is overloaded

     

     

    “Many of the applications submitted get lost,” says a senior pain physician. “Patients wait for weeks for an answer, only to discover that the forms they worked so hard to obtain have been lost.”

     

    The technical difficulties experienced by patients has been addressed in a report by State Comptroller Yosef Shapirol, which was published in June. “Since the establishment of the medical cannabis unit, hundreds of complaints have been submitted regarding its handling of applications,” said Shapiro.

     

    “The complaints reveal that patients face excessive bureaucracy when seeking to obtain medical cannabis. Many complaints are about lost or unaccounted for application forms, lost forms and considerable delays in handling submissions. Often, patients are not informed of the status of their application… 83% of complaints were found to be valid or were corrected following intervention from the comptroller’s office.”

     

    Zohar Chaim, a patient suffering from severe headaches, describes the excruciating pain he endured before he began to use cannabis. But doctors insisted on prescribing him conventional medication instead, including morphine tha left him unable to function.

     

    Until he obtained his medical cannabis license, Chaim would purchase cannabis on the black market for NIS 100 per gram (approx. $25), and he spent over NIS 8,000.

     

    Even those who do get a permit are still not free to focus on their lives and healing. The Health Ministry requires that permits be issued for a period of six to 12 months, and are conditioned on close medical follow-up.

     

    Application renewals must be submitted at least 25 working days before the license expires, so many patients are forced to deal with the bureaucracy every few months.

     

    One of the main reasons for the dismal state of affairs is the Health Ministry’s contradictory role: on the one hand it is tasked with issuing medical cannabis licenses; on the other hand, it is also a gatekeeper for the state, which still considers cannabis a dangerous drug.

     

    The primary — and legitimate — concern is that the cannabis will make its way into the black market. “We are very uneasy with the widespread use of medical cannabis, and definitely with non-medical cannabis use,” Health Ministry Director General Moshe Bar Siman Tov told the Knesset Committee on Drug and Alcohol Abuse.

     

    “We are responsible for public health and the nation’s long-term health, and we see ourselves responsible that this substance goes from people we have given it to, to those who should not have it. We are working by the book, but I repeat: I am uneasy with how it works,” he said.

     

    Health cooperatives and doctors are also responsible for the obstacles in obtaining a cannabis license as pain clinics are intermittently closed.

    The health cooperatives do not encourage doctors to submit the required forms. On the contrary, they often make it difficult and online block access to the forms. This may stem from an ingrained conservatism or the concern that lending legitimacy to cannabis treatment will lead to the costs eventually falling upon them.

     

    “They fail to understand that patients suffering from amputations or post-traumatic stress disorder can cease to be a burden on the system for only NIS 370 — the monthly cost of cannabis,” says a Health Ministry official.

     

    Critics point out the absurdity that doctors can easily issue prescriptions for hard drugs, many of them addictive, without any supervision, while cannabis — a much milder, non-addictive drug — is so hard to obtain.

     

    Most doctors in Israel support medical cannabis. A recent survey conducted among 80 pain specialists at Ichilov Hospital in Tel Aviv reveals that 63% believe that cannabis treatment is effective. Only five percent of doctors see no benefit whatsoever.

     

     (Photo: Shutterstock)

    (Photo: Shutterstock)

     

    Most doctors noted that they encountered very light side effects as a result of cannabis treatment, and only 12% believe that cannabis is more harmful than opiates when dealing with chronic pain. “There is good reason to consider giving cannabis at an earlier point of treatment,” said Dr. Haggai Sharon, a senior pain specialist at the hospital.

     

    But despite the wide support among doctors, in practice, many hesitate to prescribe medical cannabis to patients. Only a limited number of physicians regularly issue cannabis referrals and the queues to see them are very long. One patient said that she received an appointment for March 2020.

     

    Many patients have been subject to suspicion and humiliation when asking for a cannabis referral. “The approach to pain is very medication focused,” says Zohar Chaim. “Instead of focusing on my suffering, they push medications that don’t help. One doctor even told me to go purchase cannabis on the black market.”

     

    In order to help standardize the issue, the Health Ministry initiated reforms aimed at setting standards for growing and producing medical cannabis.

     

    “Although it is not listed as a medication, we want to make the use of medical cannabis similar to conventional medication,” says Yuval Landshaft, director of the medical cannabis unit in the Health Ministry. “A patient will receive a prescription from his doctor and take it to the pharmacy where he will receive high quality cannabis, just like medicine… not like stuff which is produced in backyards and basements.”

     

    Last April, the ministry began a pilot launch for selling cannabis at pharmacies. But although it was meant to include some 20 pharmacies and aroused a lot of public and media interest, in practice only a few pharmacies took part and no more than 200 patients participated.

     

    Another criticism of the planned reforms is the price. Currently, patients pay a set price of NIS 370 a month regardless of the amount they were prescribed. But starting soon it is set to be sold for NIS 120-140 for 10 grams. Patients requiring more than 50 grams will be paying significantly more. The street price for cannabis is between NIS 70-100 for one gram.

     

    Zohar Chaim: Physicians swear an oath to the patient, not drug companies

    Zohar Chaim: Physicians swear an oath to the patient, not drug companies

     

    In response to criticisms related to the price, Landshaft says: “Clearly a set price that disregards quantity is problematic and encourages use even without medical justification, therefore it was decided to base the price on quantity.

     

    “About 85% of patients use 40 grams or less and will not be paying more than they currently do… Regarding the 5% of patients who require a large quantity, the Health Ministry is seeking a solution.”

     

    According to the ministry, the reforms are set to be implemented doing the first quarter of 2019 and “will solve many of the problems raised in this article.” They also said that more than 100 doctors will be licensed to issue cannabis to patients and that more patients suffering from various conditions will become eligible.

     

    But many doubt that the reforms will be implemented as scheduled. Patients who are suffering seek a solution now and not in a few months. “The physician’s oath is toward the patients, not the drug companies,” says Zohar Chaim. “I want everyone from the ministry who is involved in the matter to put themselves in our shoes, to imagine they have a massive migraine and they have to wait months for medicine…”

     

    The Ministry of Health said in response: “Regulation of medical cannabis as it is currently performed in Israel is the first of its kind in the world, and progress must be made with great care and responsibility. This is a complex and unique process.

     

    “Thanks to the intensive work of the ministry and the cannabis unit, there are more than 42,000 patients in Israel with a cannabis license —the highest in the world in relation to population.

     

    “The fact that the ministry seeks to better the lives of patients does not meant that any amount of cannabis will be issued to whoever wants, but rather that each case will be examined on its merits. Applications for a license are constantly increasing and nevertheless, they do their best to keep up.

     

    “It is true that lately there has been a large backlog but we are working to speed up the process and make it more efficient. Some of the workload has been transferred to an outside firm and a computer program will be available for patients to upload their medical forms. After they are checked, the patient will be able to print out their own license and take it to the pharmacy. In addition, 150 doctors will be qualified to issue cannabis licenses themselves for a small fee (NIS 290).

     

    “The pharmacy pilot was designed to examine the chain of production and the interfaces, and has been used to find and fix malfunctions. The reforms will take effect during the first quarter of 2019, and new or renewed license holders will be directed to a pharmacy in order to purchase supervised cannabis products. Those already holding a license will continue to purchase cannabis from the growers until their license is renewed, a process that will take up to a year.” 

     

    Source link

    Hidradenitis Suppurativa Market 2018 to 2023 Future Demand Analysis, Industry sizes, Share, opportunity and Market overviews

    Premium Research Report on Hidradenitis Suppurativa Market made available by Worldwide Market Reports 2018 – 2023 offering latest Industry review, Regional market, Opportunities, Emerging growth factor, Drivers, challenges, Characterization, application, innovation, openings, future guide, and most recent market competitors joined with their market share. The report covers a thorough perception of the Keywaord market and identifies the key trends associated with the different sectors of the market.

    This Hidradenitis Suppurativa market report focuses on Value Chain Analysis and exhaustive Market information about the Top Manufacture with future plans and financial performance. In this report, the study covers Recent Developments, Updates in Key players, Market regulation and market trends. We also give the details solution about the business trends, latest geographical market segmentation, and market challenges. On the basis of Consumers Analysis, gross margin analysis, distribution analysis, and local consumption analysis it’s will help to grow your business on the top across the world.

    Get PDF Sample Copy of This Report: @ https://www.worldwidemarketreports.com/sample/179309

    The report also provides a competitor analysis of Key Trends & advanced technologies. The Hidradenitis Suppurativa (Thousands Units) and Revenue (Million USD) Market Split by Key players such as Company A, Company B, Company C… Continued.

    The Hidradenitis Suppurativa Market coverage of this report includes:

    1. It helps every manufacturer with respect to the company profile, a generic overview, and the products offered have also been given.
    2. The report developed on product sales, revenue increase, price patterns, and gross margins.
    3. The Data will help with respect to the most recent news that each organization is involved in has been providing in the observation study.
    4. Its provide details Analysis of the pivotal competitors and their future opportunities in the industry.
    5. The report explains on the item deals, income gathered, value examples, and gross margin.

    Major Regions covers:

    Geographically, this report split global into several key Regions, with sales (MT), revenue (Million USD), and market share and growth rate of Hidradenitis Suppurativa for these regions, covering

    North America (USA, Canada and Mexico)
    Europe (Germany, France, UK, Russia and Italy)
    Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
    South America (Brazil, Argentina, Columbia etc.)
    The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

    The Hidradenitis Suppurativa market report includes the finding the detailed study of competitive analysis of the industry of the industry. The Hidradenitis Suppurativa market reports also give key developments strategies and policies along with manufacturing strategy. The Hidradenitis Suppurativa reports a cover the exact study of the key players to figure out their business strategies, annual revenue, company profile and their allotment to the global Hidradenitis Suppurativa market share. The key detail of the Hidradenitis Suppurativa industry such as the supply chain analysis.

    Have Any Query? Ask Our Expert at @ https://www.worldwidemarketreports.com/quiry/179309

    About Worldwide Market Reports:

    Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. WMR well-researched inputs that encompass domains enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

    Source link

    Inflarx N.V. (NASDAQ:IFRX) Sellers Decreased Their Shorts By 1.57% – Enbulletin

    Change of 1.57% for Inflarx N.V. (NASDAQ:IFRX)’s shares shorted was reported. In December was published IFRX’s total 231,600 shares shorted by FINRA. The 235,300 previous shares are down with 1.57%. Inflarx N.V. (NASDAQ:IFRX) has 11,900 shares average volume. It’ll cost 20 days for IFRX to recover its former position. Inflarx N.V.’s shares shorted float is 3.2%.

    Ticker’s shares touched $26.81 during the last trading session after 10.69% change.Currently InflaRx N.V. is uptrending after 63.49% change in last December 26, 2017. IFRX has 38,247 shares volume. IFRX outperformed the S&P 500 by 63.49%.

    InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States.The firm is worth $688.00 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases.Last it reported negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.

    For more InflaRx N.V. (NASDAQ:IFRX) news released recently go to: Globenewswire.com, Nasdaq.com, Nasdaq.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “InflaRx N.V. Reports First Quarter 2018 Financial & Operating Results – GlobeNewswire” released on May 17, 2018, “Itafos Posts Updated Corporate Presentation to Website – Nasdaq” on December 03, 2018, “Facing big loss, Swiss asset manager GAM cuts staff, dividend – Nasdaq” with a publish date: December 13, 2018, “InflaRx NV Announces Appointment of Jens Holstein to Board of Directors – Nasdaq” and the last “Arco Platform Limited Reports Third Quarter 2018 Financial Results – Nasdaq” with publication date: November 27, 2018.

    InflaRx N.V. (NASDAQ:IFRX) Analyst Ratings Chart

    Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.


    Source link

    AK Steel Holding (AKS) EPS Estimated At $0.12; Inflarx N.V. (IFRX) Shorts Lowered By 1.57% – The DMinute

    AK Steel Holding Corporation (NYSE:AKS) Logo

    Inflarx N.V. (NASDAQ:IFRX) had a decrease of 1.57% in short interest. IFRX’s SI was 231,600 shares in December as released by FINRA. Its down 1.57% from 235,300 shares previously. With 11,900 avg volume, 20 days are for Inflarx N.V. (NASDAQ:IFRX)’s short sellers to cover IFRX’s short positions. The SI to Inflarx N.V.’s float is 3.2%. The stock increased 0.71% or $0.17 during the last trading session, reaching $24.22. About 3,423 shares traded. InflaRx N.V. (NASDAQ:IFRX) has risen 63.49% since December 26, 2017 and is uptrending. It has outperformed by 63.49% the S&P500. Some Historical IFRX News: 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6

    Analysts expect AK Steel Holding Corporation (NYSE:AKS) to report $0.12 EPS on January, 29.They anticipate $0.18 EPS change or 300.00% from last quarter’s $-0.06 EPS. AKS’s profit would be $37.87 million giving it 4.50 P/E if the $0.12 EPS is correct. After having $0.21 EPS previously, AK Steel Holding Corporation’s analysts see -42.86% EPS growth. The stock decreased 6.90% or $0.16 during the last trading session, reaching $2.16. About 8.70 million shares traded. AK Steel Holding Corporation (NYSE:AKS) has declined 46.53% since December 26, 2017 and is downtrending. It has underperformed by 46.53% the S&P500. Some Historical AKS News: 01/05/2018 – AKS, U.S. STEEL FALL AFTER U.S. EXTENDS TEMPORARY TARIFF RELIEF; 30/05/2018 – AK Steel Launches TRAN-COR® X — New Grain Oriented Electrical Steel for Power Transformers; 23/04/2018 – DJ AK Steel Holding Corporation, Inst Holders, 1Q 2018 (AKS); 21/05/2018 – U.S. slaps heavy duties on Chinese steel from Vietnam; 10/05/2018 – AK Steel Research and Innovation Team Receives Award from Auto/Steel Partnership For Contribution to Research on Innovative Lightweight Steel Solutions; 13/03/2018 – IAM MEMBERS RATIFY LABOR PACT FOR AK STEEL MIDDLETOWN WORKS; 13/03/2018 – AK STEEL HOLDING CORP – CO SAID CONTRACT WAS RATIFIED IN VOTING HELD ON MARCH 12, 2018; 13/03/2018 – IAM Members Ratify Labor Agreement For AK Steel Middletown Works; 01/05/2018 – AK STEEL URGES OTHER INDUSTRIES TO WAKE UP TO UNFAIR TRADE RISK; 03/05/2018 – AK Steel Research and Innovation Employees Receive Prestigious Award for Work on Third Generation Advanced High Strength Steel

    InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $621.54 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.

    More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Nasdaq.com which released: “InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis – Nasdaq” on December 19, 2018, also Nasdaq.com with their article: “Endeavour Closes the Sale of Its Non-Core Tabakoto Mine – Nasdaq” published on December 24, 2018, Nasdaq.com published: “Verkkokauppa.com Oyj has decided on the transition to IFRS reporting – Nasdaq” on December 12, 2018. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Nasdaq.com and their article: “Correction of previous press release: Etrion announces 2018 guidance update – Nasdaq” published on December 21, 2018 as well as Nasdaq.com‘s news article titled: “Nanotech Announces Fourth Quarter and Year-End Results – Nasdaq” with publication date: December 19, 2018.

    Since August 15, 2018, it had 2 insider buys, and 0 selling transactions for $40,550 activity. $30,300 worth of AK Steel Holding Corporation (NYSE:AKS) shares were bought by Newport Roger K. 2,500 shares were bought by Alter Joseph C, worth $10,250 on Wednesday, August 15.

    Investors sentiment increased to 1.08 in 2018 Q3. Its up 0.11, from 0.97 in 2018Q2. It is positive, as 31 investors sold AK Steel Holding Corporation shares while 57 reduced holdings. 38 funds opened positions while 57 raised stakes. 203.84 million shares or 1.64% more from 200.55 million shares in 2018Q2 were reported. State Board Of Administration Of Florida Retirement System owns 160,526 shares or 0% of their US portfolio. Arizona State Retirement Sys stated it has 457,692 shares. Wells Fargo And Co Mn has 0% invested in AK Steel Holding Corporation (NYSE:AKS). Carlson L P invested in 0.04% or 655,000 shares. 394,532 were reported by Engineers Gate Manager L P. Iberiabank has 10,975 shares. State Teachers Retirement System invested 0% of its portfolio in AK Steel Holding Corporation (NYSE:AKS). Barclays Public Limited Co stated it has 378,349 shares. Bnp Paribas Asset Management owns 48,583 shares or 0% of their US portfolio. Bancshares Of America De invested in 0% or 566,927 shares. Moreover, Putnam Ltd Liability Corporation has 0% invested in AK Steel Holding Corporation (NYSE:AKS) for 131,330 shares. Moreover, Vanguard Grp Inc has 0.01% invested in AK Steel Holding Corporation (NYSE:AKS). York Capital Mgmt Advisors Llc accumulated 1.00 million shares. Millennium Mngmt Ltd Liability Co, a New York-based fund reported 1.95 million shares. Berkshire Asset Mgmt Ltd Pa accumulated 10,000 shares.

    AK Steel Holding Corporation, through its subsidiary, AK Steel Corporation, produces flat-rolled carbon, stainless, and electrical steels and tubular products in the United States and internationally. The company has market cap of $681.57 million. It produces flat-rolled carbon steel products, including coated, cold-rolled, and hot-rolled carbon steel products; specialty stainless and electrical steels in sheet and strip forms; and carbon and stainless steel that is finished into welded steel tubing. It currently has negative earnings. The firm also buys and sells steel and steel products, and other materials; and produces metallurgical coal from reserves in Pennsylvania.

    More notable recent AK Steel Holding Corporation (NYSE:AKS) news were published by: Benzinga.com which released: “Steel Stocks Have Wall Street’s Attention (NYSE:X)(NASDAQ:STLD)(NUE)(AKS) – Benzinga” on November 27, 2018, also Seekingalpha.com with their article: “AK Steel – The Bear Case Is Unfolding – Seeking Alpha” published on November 28, 2018, Fool.com published: “2 Steel Stocks That Have a Killer Advantage – The Motley Fool” on December 01, 2018. More interesting news about AK Steel Holding Corporation (NYSE:AKS) were released by: Bizjournals.com and their article: “Fifth Third stock plummets with Dow, other banks – Cincinnati Business Courier” published on December 04, 2018 as well as 247Wallst.com‘s news article titled: “Altria, General Electric Slip into Monday’s 52-Week Low Club – 24/7 Wall St.” with publication date: November 26, 2018.

    Among 4 analysts covering AK Steel Holding (NYSE:AKS), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. AK Steel Holding had 4 analyst reports since July 9, 2018 according to SRatingsIntel. The firm has “Hold” rating given on Monday, July 9 by Deutsche Bank. The stock of AK Steel Holding Corporation (NYSE:AKS) earned “Buy” rating by Bank of America on Friday, September 7. The rating was upgraded by Morgan Stanley on Monday, August 27 to “Overweight”.

    AK Steel Holding Corporation (NYSE:AKS) Institutional Positions Chart

    Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



    Source link